Akeso, Inc. (AKESF) Stock Price & Analysis
Akeso, Inc. (AKESF) closed at USD 10.84 on Thursday, October 22, 2026, down 10.68% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 12.14; the Oct 22, 2026 session ranged USD 10.65–11.1 on volume of 1,200 shares. Market capitalization is $9.99B, with a 52-week range of USD 10.5–19.49 (PNK). Source: Nexqual, retrieved October 23, 2026 at 16:39 UTC.
Also available as compact Markdown for AI agents: nexqual.com/AKESF.md
Key facts (AKESF)
- Analysts: None.
- Total return with dividends: 1Y -27.9% vs S&P 500 +14.6%; 5Y +116.8% vs S&P 500 +77.3%.
- Next earnings: 2026-08-27, EPS estimate USD —, revenue estimate $0K.
Analysts (AKESF)
Consensus None.
Total return (dividends reinvested) (AKESF)
| 1Y (from 2025-10-23) | 5Y (from 2023-05-15) | |
|---|---|---|
| Total return | -27.9% | +116.8% |
| S&P 500 (SPY) | +14.6% | +77.3% |
| Per year | -28.0% | +25.2% |
| Volatility (annualized) | 61.1% | 56.0% |
| Max drawdown | -45.6% (Apr 2026→Jun 2026) | -54.2% (Aug 2025→Jun 2026) |
AKESF analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends Dec 2026) | — | — | — | $4.62B | — |
| Next fiscal year (ends Dec 2027) | — | — | — | $6.99B | — |
Key Statistics (as of October 23, 2026 at 16:39 UTC)
| Price | USD 10.84 |
|---|---|
| Change | ▼ 10.68% (down) |
| Previous Close | USD 12.14 |
| Open | USD 11 |
| Day Range | USD 10.65 – 11.1 |
| 52-Week Range | USD 10.5 – 19.49 |
| Volume | 1,200 shares |
| Market Cap | $9.99B |
| Exchange | PNK |
Technical Analysis (AKESF)
Nexqual's technical model rates AKESF "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 16:39 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.27 (neutral) |
| vs SMA50 | Below (USD 12.36) |
| MACD | -0.27 (negative) |
Analyst Ratings (AKESF)
Wall Street analysts rate AKESF "None", per Nexqual as of October 23, 2026 at 16:39 UTC.
| Consensus Rating | None |
|---|
Earnings (AKESF)
| Next Earnings Date | 2026-08-27 |
|---|
Source: Nexqual, October 23, 2026 at 16:39 UTC.
Financials & Fundamentals (AKESF)
| Total Revenue | $3.45B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +27.90% |
| Gross Margin | +73.59% |
| Operating Margin | -31.87% |
| Profit Margin | -28.03% |
| ROE | -13.58% |
| Debt / Equity | 0.6 |
| Current Ratio | 4.01 |
| Total Cash | $9.16B |
| Total Debt | $4.98B |
Source: Nexqual, October 23, 2026 at 16:39 UTC.
Financial Health Score (AKESF)
Nexqual rates Akeso, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 16:39 UTC.
| Growth | Strong — Revenue +44% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 74%, operating -32% (last 12 months) |
| Balance Sheet | Strong — CNY 9.16B cash vs CNY 4.98B debt, net cash position |
| Cash Flow | Weak — Operating cash flow -CNY 430M (TTM) |
| Efficiency | Critical — ROE -14%, ROA -4.5% |
Ownership (AKESF)
| Insider Ownership | +21.21% |
|---|---|
| Institutional Ownership | +32.14% |
| Shares Outstanding | 921.14M |
| Float | 721.55M |
Source: Nexqual, October 23, 2026 at 16:39 UTC.
Leadership (AKESF)
Akeso, Inc. is led by Yu Xia, Founder, CEO, President & Chairwoman, per Nexqual as of October 23, 2026 at 16:39 UTC.
| Founder, CEO, President & Chairwoman | Yu Xia |
|---|---|
| Co-Founder, Executive VP, CSO & Executive Director | Baiyong Li |
| Co-Founder, Senior VP & Executive Director | Zhongmin Wang |
| Co-Founder, Senior VP & Executive Director | Peng Zhang |
| Senior Vice President | Yu Xia |
Major Backers & Investors (AKESF)
Notable institutional backers of Akeso, Inc. include Fidelity, according to Nexqual as of October 23, 2026 at 16:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.34% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.43% |
| BlackRock | 1.12% |
| State Street | 0.11% |
Source: Nexqual, October 23, 2026 at 16:39 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PCVX | Vaxcyte, Inc. | USD 61.32 | ▼ 2.43% |
| KRYS | Krystal Biotech, Inc. | USD 314.04 | ▼ 1.9% |
| MDGL | Madrigal Pharmaceuticals, Inc. | USD 443.19 | ▼ 2.24% |
| KYMR | Kymera Therapeutics, Inc. | USD 110.72 | ▼ 0.12% |
| PTGX | Protagonist Therapeutics, Inc. | USD 138.99 | ▼ 0.39% |
| TWST | Twist Bioscience Corporation | USD 137.78 | ▲ 1.71% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 16:39 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt